



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 11/02, C12P 21/04 A01N 63/04, C12N 1/14 // (C12P 21/04, C12R 1/645) (C12N 1/14, C12R 1/645)	A1	(11) International Publication Number: WO 92/05191 (43) International Publication Date: 2 April 1992 (02.04.92)
(21) International Application Number: PCT/DK91/00273 (22) International Filing Date: 17 September 1991 (17.09.91) (30) Priority data: 2236/90 17 September 1990 (17.09.90) DK (71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK). (72) Inventors; and (75) Inventors/Applicants (for US only) : NIELSEN, Ruby, Ione [DK/DK]; Gedebacken 9, DK-3520 Farum (DK). BREINHOLT, Jens [DK/DK]; Bagsærdal 2, st.th., DK-2880 Bagsværd (DK). JENSEN, Georg, Wilhelm [DK/DK]; Klirevænget 69, DK-2880 Bagsværd (DK).		(74) Agent: NOVO NORDISK A/S; Patent Department, Novo Allé, DK-2880 Bagsværd (DK). (81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, SD, SE, SE (European patent), SN (OAPI patent), SU⁺, TD (OAPI patent), TG (OAPI patent), US. Published With international search report.
(54) Title: FUNGICIDALLY ACTIVE COMPOUNDS (57) Abstract <p>Novel compounds of the general composition I, Lactate (1), Glycine (1), Valine (4), Isoleucine (1), pipecolic acid (1), Aspartic acid (1), Tyrosine (1), wherein each amino acid residue independently may occur in L- or D- form, and wherein the number in parenthesis indicates the number of occurrences of each moiety, and derivatives thereof are disclosed. The compounds are producible by aerobic cultivation on suitable nutrient media under suitable conditions of a strain of the fungus <i>Curvularia sp.</i>, subsequent recovery of the active component from the fermentation medium, and optionally modifying the active compound to obtain a compound of the desired general composition. Disclosed are also microorganisms capable of producing said compounds, compositions containing said compounds, and the use of such compositions for controlling fungi in crops, and in the preservation of wood, paints, cosmetics, and edible products.</p>		

BEST AVAILABLE COPY

+ DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

Title: FUNGICIDALLY ACTIVE COMPOUNDS

FIELD OF THE INVENTION


This invention relates to novel fungicidally active compounds, methods of producing
5 such compounds, microorganisms capable of producing said compounds, compositions
containing said compounds, and the use of such compositions for controlling fungi in
valuable crops, animals, including birds and mammals, and in the preservation of wood
and timber, paints, cosmetics, foods and feeds.

10 BACKGROUND OF THE INVENTION

For a number of years it has been known that various microorganisms produce
metabolites exhibiting biological activity so as to be useful as biocides for combating
diseases and pests.

15 Especially it has been known that some species of the genus *Curvularia* produce dif-
ferent metabolites exhibiting biological activity, in particular as phytotoxins. However,
none of these metabolites are known to be fungicides. *C. lunata* (Wakk.) Boed was
found to produce at least two phytotoxins. They cause necrotic spots on plant leaves
even when they are highly diluted. (F. Macrí and A. Vianello, *Physiological Plant*
20 *Pathology* 8:325-331, 1976). The toxins are phytotoxins and are non host specific. Host
specific toxins have been isolated from culture filtrates of *C. pallescens* Boedijn and
from diseased host leaves attacked by this species (Olufolaji, *Cryptogamic Mycol.*
7(4):335-342, 1986). These toxic substances gave chlorotic spots to maize plants. They
later became necrotic similar to in-vivo symptoms of the disease caused by *C.*
25 *pallescens*.

Curvularin, a macrocyclic metabolite, has been isolated from a *Curvularia* species (O.
C. Musgrave, *J. Chem Soc.*, 1956, 4301) and from *C. lunata* (Coombe et al, *Aust. J.*
Chem. 21:783, 1968). The compound has the formula $C_{16}H_{20}O_5$, (molecular weight 292.3)
30 and has the formula 1 below:



5

Crude curvularin was isolated as colourless or pale yellow-brown crystals.

Neither curvularin nor the crude filtrates from *Curvularia* showed anti-bacterial activity (against *Bacillus subtilis*, *Escherichia coli*, and *Staphylococcus aureus*) or anti-fungal activity (spore germination test with *Penicillium digitatum*).

10

None of the above compounds are useful for combating plant diseases and pests because they are strong phytotoxins.

15 Although progress has been made in the field of identifying and developing biological biocides for combating various diseases and pests in plants and animals of agronomical importance, most of the biocides in use are still synthetic compounds that are difficult to decompose in nature and have a broad spectrum of activity.

20 In the last decade or so there has been a still increasing concern for the impact of such biocides on the environment and the ecosystems surrounding farmlands, and consequently there exists an outspoken need for biocides that are more specific in their activity, and are readily degradable in the natural environment.

25 A number of compounds related to the compounds disclosed through this invention have been disclosed in European Publication No. EP 360 760 (Sandoz AG), published 28.3.1990. These compounds are disclosed as being produced by the fungal genus *Septoria*, and as having interesting pharmacological properties, e.g. antifungal activity in animals against yeast and yeast-like species causing systemic attacks. The publication
30 contains only reference to one test against *Candida*, and no reference to which of the 82 exemplified compounds were tested for this activity, but states that the most preferred compound can be represented by the formula:

cyclo-[Pec-MeVal-Val-MeAsp-Melle-Melle-Gly-MeVal-TyrOMe-D-Lact] (Example 1, first compound).

SUMMARY OF THE INVENTION

- 5 As indicated above known metabolites from the mold genus *Curvularia* all have exhibited a strong phytotoxic activity, but it has now surprisingly been found that fungi belonging to said genus also produce metabolites that exhibit strong antifungal activity, and that are substantially without phytotoxic activity.
- 10 The present invention in its first aspect concerns a group of novel compounds comprising compounds having the general composition I,
- Lactate (1), Glycine (1), Valine (4), Isoleucine (1),
pipecolic acid (1), Aspartic acid (1), Tyrosine (1) (I)
- wherein each amino acid residue independently may occur in L- or D-form, and
- 15 wherein the number in parenthesis indicates the number of occurrences of each moiety, and derivatives thereof.

Under this aspect the invention also relates to compounds of the composition




- 20 and derivatives thereof.

In a specific aspect the invention relates to such compounds of the general composition II


- Lactate (1), Glycine (1), Valine (1), N-Me-Valine (3),
25 N-Me-Isoleucine (1), pipecolic acid (1), N-Me-Aspartic acid (1), (II)
O-Me-Tyrosine (1),
- wherein each amino acid residue independently may occur in L- or D-form, and,
wherein the number in parenthesis indicates the number of occurrences of each moiety, and derivatives thereof.

30

In a specific aspect the invention relates to the compounds of formulae III and IV



cyclo-[Pec-MeAsp-MeVal-Val-MeVal-Melle-Gly-MeVal-TyrOMe-D-Lact] (III)



cyclo-[Pec-MeVal-Val-MeAsp-MeVal-Melle-Gly-MeVal-TyrOMe-D-Lact] (IV),

5 wherein each amino acid residue and the lactate residue independently may occur in L- or D-form, and derivatives thereof. Most preferred are the compounds wherein all the amino acid residues are in the L-form and the lactate residue is in the D-form.

In its second aspect the invention relates to processes used for the production of the novel compounds of the invention. These processes comprise use of specific microorganisms as well as chemical processes for full or semi synthetic production of said compounds.

5

In a third aspect of the invention it relates to fungicidal compositions comprising the novel compounds of the invention in combination with suitable excipients, such as diluents, carriers, etc.

- 10 The invention also relates to the use of microorganisms producing the compounds of the invention as fungicidal compositions.

Within the context of the invention it is also contemplated to combine the novel compounds of the invention with known biocides for making up novel combination
15 compositions.

Furthermore the invention in a fourth aspect relates to methods of combating plant diseases by application of compositions comprising the novel compounds of the invention to infested areas.

20

In a fifth aspect the invention relates to the use of the novel compounds of the invention for combating or controlling plant diseases, especially fungal attack.

Also the invention relates to the use of the novel compounds as preservatives and/or
25 additives to control fungi in foods and feeds, timber and wood, paints, growth media, cosmetics, etc.

Lastly the invention relates to an isolated pure culture of the microorganism *Curvularia* sp. (CMI CC No. 337159).

30

DEPOSITION OF MICROORGANISM

For the purpose of describing this invention in detail a strain of the fungus *Curvularia* sp. (CMI CC No. 337159) has been deposited with the Commonwealth Mycological Institute Culture Collection (CMI CC), Ferry Lane, Kew, Surrey TW9 3AF, England, for the purposes of patent procedure on the date indicated below. CMI CC being an international depository under the Budapest Treaty affords permanence of the deposit in accordance with rule 9 of said treaty.

	Deposit date	6 February 1990
10	Depositor's ref.	33 177
	CMI CC designation	CMI CC No. 337159

CMI CC 337159 belongs to the class Deuteromycetes, sub-class Hyphomycetidae and family Dematiaceae. The fungus is a new species of the genus *Curvularia*.

15

BRIEF DESCRIPTION OF THE DRAWING

The invention is described in further detail below with reference to the drawings, wherein

20 Fig. 1 shows a graphical representation of the stability/activity relationship with temperature and pH for a novel compound according to the invention,

Figs. 2, 3, and 4 show 400 MHz ¹H-NMR spectra of the isolated compound of the invention in CDCl₃, DMSO-d₆, and CD₃OD, respectively.

25

Fig. 5 shows a 100.6 MHz ¹³C-NMR spectrum of the isolated compound of the invention in CDCl₃.

Fig. 6 shows an infra-red (IR) spectrum of the isolated compound of the invention in 30 KBr.

Fig. 7 shows an IR spectrum of a methylated derivative in KBr, and

Fig. 8, 9, and 10 show the results of applying a compound of the invention to *Botrytis cinerea* infected strawberries, grapes, and tomatoes, respectively.

5

DETAILED DESCRIPTION OF THE INVENTION

As indicated above the invention relates in its first aspect to novel compounds of the general composition I,

- Lactate (1), Glycine (1), Valine (4), Isoleucine (1),
10 pipecolic acid (1), Aspartic acid (1), Tyrosine (1) (I)
wherein each amino acid residue independently may occur in L- or D-form, and
wherein the number in parenthesis indicates the number of occurrences of each
moiety, and derivatives thereof.

- 15 Within this aspect the invention furthermore comprises such compounds further
comprising a lactone ring; and derivatives thereof.

The invention moreover comprises such compounds having the composition



- 20 and derivatives thereof.

Within this aspect the derivatives referred to above particularly comprise such
compounds having been alkylated, hydroxylated, glycosylated, halogenated, reduced,
oxidized, hydrolysed, or esterified.


25

In a specific aspect the invention relates to such compounds of the general composition
II


- Lactate (1), Glycine (1), Valine (1), N-Me-Valine (3),
N-Me-Isoleucine (1), pipecolic acid (1), N-Me-Aspartic acid (1), (II)
30 O-Me-Tyrosine (1),

wherein each amino acid residue independently may occur in L- or D-form, and, wherein the number in parenthesis indicates the number of occurrences of each moiety, and derivatives thereof.

5 As a specific example the invention relates to the compounds of formulae III and IV



cyclo-[Pec-MeAsp-MeVal-Val-MeVal-Melle-Gly-MeVal-TyrOMe-D-Lact] (III)



(IV)
 cyclo-[Pec-MeVal-Val-MeAsp-MeVal-Melle-Gly-MeVal-TyrOMe-D-Lact] (IV),

wherein each amino acid residue and the lactate residue independently may occur in
 5 L- or D-form, and derivatives thereof. Most preferred are the compounds wherein all
 the amino acid residues are in the L-form and the lactate residue is in the D-form.

The compounds of formulae III and IV were isolated as metabolites from a novel
 species of the genus *Curvularia*, *Curvularia* sp. (CMI CC No. 337159).

10

Compounds of this class of organic structures with the formulae III and IV are novel.
 The closest reference is EP 360 760 discussed above. The compounds of EP 360 760
 have as the main difference from those of the present invention that they always
 comprise two neighbouring isoleucine residues.

15

Although compounds closely related to the compounds of this invention are disclosed
 in EP 360 760, the compounds there would not be considered for agronomical use.
 This is due to the high toxicity (approximately 100 mg/kg p.o.) and low antifungal

activity (dosage 25 to 300 mg/kg, daily dosage of 300 to 3000 mg) as exemplified towards *Candida* on pages 47 to 49 of EP 360 760.

Furthermore EP 360 760 only indicates pharmaceutical usage of the related
5 compounds. Consequently the surprising specificity and activity for the agronomical use of the compounds of the present invention can in no way be inferred from EP 360 760. According to its second aspect the invention relates to processes for the production of the novel compounds of the composition I.

10 The compounds of formulae III or IV may be prepared by aerobic cultivation on suitable nutrient media under conditions hereinafter described with a strain of a fungus belonging to the genus *Curvularia*, especially the fungus *Curvularia sp.* (CMI CC 337159), and thereafter recovering the active component from the biomass and from the fermentation medium.

15

The natural metabolite may subsequently be modified chemically in order to obtain various derivatives thereof. The derivatives may be produced in order to improve certain properties with the metabolite such as its solubility in aqueous media, its hydrophobicity, hydrophilicity, stability, specificity, etc.

20

It is also contemplated that compounds according to the invention may be produced by well known chemical synthetic processes using available starting materials.

Derivatives of related compounds and methods for producing such derivatives hereto
25 are disclosed in detail in EP 360 760, which is hereby incorporated by reference.

A specific type of derivatives from the compounds of formulae III and IV are such compounds wherein the lactone ring has been opened.

30 One group of derivatives is compounds of composition I, II, III or IV, wherein one or several hydroxy and/or amino groups have been glycosylated with one or more sugar moieties.

Another group comprises compounds of composition I, II, III or IV, wherein one or several hydroxy and/or amino groups have been acylated with organic acids into ester/amide groups.

- 5 A further group of derivatives is compounds of composition I, II, III, or IV, wherein one or several hydroxy and/or amino groups have been alkylated into alkyl ethers/amines.

- A further group of derivatives is compounds of composition I, II, III, or IV, wherein
10 one or several groups have been substituted by halogenation into compounds, wherein one or more groups are halogens.

- A further group of derivatives is compounds of composition I, II, III, or IV, wherein one or several groups have been altered by reduction of one or more groups in the
15 compound obtained.

- A further group of derivatives is compounds of composition I, II, III, or IV, wherein one or several groups have been altered by oxidation of one or more groups in the compound obtained.
20

A further group of derivatives is compounds of composition I, II, III, or IV, wherein one or several groups have been altered by hydrolysis of one or more groups in the compound obtained.

- 25 Although the invention discussed herein below, principally deals with the specific strain CMI CC 337159, it is well known in the art that the properties of microorganisms may be varied naturally and artificially. Thus all strains belonging to the genus *Curvularia* including variants, recombinants and mutants, whether obtained by natural selection, produced by the action of mutating agents such as ionizing radiation or ultraviolet
30 irradiation, or by the action of chemical mutagens such as nitrosoguanidine, are included in this invention.

It is well known that a fungus is able to produce closely related metabolites (cf. EP 360 760, where three related compounds were produced by the same fungus) of the same or similar activity, but with minor differences in chemical structure. The present invention is therefore meant also to encompass such closely related compounds
5 produced by CMI CC 337159.

Depending on the circumstances such as the crop wherein fungi are to be combated, the environmental conditions or other factors, a composition of the invention in addition to said fungicidally active compounds of the invention may also contain other
10 active ingredients such as other biocides, such as fungicides, herbicides, insecticides, nematocides, acaricides, or plant nutrients, plant growth regulators, or fertilizers.

Examples of other fungicides which can be combined with the active compounds of the invention include especially ergosterol biosynthesis inhibitors ("EBIs"). These are
15 generally imidazole or triazole derivatives and examples include those known by the common names prochloraz, triadimefon, propiconazole, diclobutrazol, triadiminol, flusilazole, flutriafol, myclobutanil, penconazole, quinconazole, imazalil and diniconazole. Examples of non azole EBIs include nuarimol, fenarimol, fenpropimorph, tridemorph and fenpropidine. Other fungicides which can be combined with the
20 enzyme preparation of the invention include anilides, e.g. carboxin, metalaxyl, furalaxyl, ofurace, benalaxyl, mepronil, flutolanil, pencycuron and oxadixyl; benzimidazoles, e.g. benomyl and carbendazim; carbamates, e.g. maneb, mancozeb and propamocarb; dicarboximides, e.g. iprodione, vinclozolin and procymidone; phosphorus derivatives, e.g. pyrazophos, tolclofos-methyl and fosetyl aluminum; and miscellaneous compounds,
25 including dithiocarbamates, bisdithiocarbamates, imidazoles, triazoles, phthalonitriles, polyhalogenalkylthio compounds, iminoctadine, guazatine, dicloran, chlorothalonil, pyrifexox, ethirimol, cymoxanil, phenyl pyrroles, thiocycofenes, pyrimidines, and anilazine.

30 For combating fungi in animals including humans the composition of the invention would usually comprise said active compounds of the invention alone with a physiologi-

cally compatible carrier or diluent, but it may also be combined with other active ingredients such as an antibioticum.

A fungicidal composition according to the invention having a fungicidally active
5 compound of the invention as its active ingredient may for agronomical and/or horticultural applications be formulated by mixing the active principle with suitable inert and compatible carriers or diluents to obtain a composition of the type generally used in agricultural compositions such as a wettable powder, an emulsifiable concentrate, a concentrated emulsion, a granular formulation, a water soluble powder, an
10 alginate, a xanthan gum and/or an aerosol. As solid carriers bentonite, diatomaceous earth, apatite, gypsum, talc, pyrophyllite, vermiculite, ground shells, and clay may be mentioned. A surface active agent may also be added with the purpose of producing a homogeneous and stable formulation.

15 The diluent or carrier in the composition of the invention can as indicated be a solid or a liquid optionally in association with a surface-active agent, for example a dispersing agent, emulsifying agent or wetting agent. Suitable surface-active agents include anionic compounds such as a carboxylate, for example a metal carboxylate of a long chain fatty acid; an N-acylsarcosinate; mono- or di-esters of phosphoric acid
20 with fatty alcohol ethoxylates or salts of such esters; fatty alcohol sulphates such as sodium dodecyl sulphate, sodium octadecyl sulphate or sodium cetyl sulphate; ethoxylated fatty alcohol sulphates; ethoxylated alkylphenol sulphates; lignin sulphonates; petroleum sulphonates; alkyl aryl sulphonates such as alkyl-benzene sulphonates or lower alkylnaphthalene sulphonates, e.g. butyl-naphthalene sulphonate; salts of sul-
25 phonated naphthalene-formaldehyde condensates; salts of sulphonated phenol-formaldehyde condensates; or more complex sulphonates such as the amide sulphonates, e.g. the sulphonated condensation product of oleic acid and N-methyl taurine or the dialkyl sulphosuccinates, e.g. the sodium sulphonate of dioctyl succinate. Non-ionic agents include condensation products of fatty acid esters, fatty alcohols, fatty
30 acid amides or fatty-alkyl- of alkenyl-substituted phenols with ethylene oxide, fatty esters of polyhydric alcohol ethers, e.g. sorbitan fatty acid esters, condensation products of such esters with ethylene oxide, e.g. polyoxyethylene sorbitan fatty acid esters, block

copolymers of ethylene oxide and propylene oxide, acetylenic glycols such as 2,4,7,9-tetraethyl-5-decyn-4,7-diol, or ethoxylated acetylenic glycols.

Examples of a cationic surface-active agent include, for instance, an aliphatic mono-,
5 di-, or polyamine as an acetate, naphthenate or oleate; an oxygen-containing amine
such as an amine oxide or polyoxyethylene alkylamine; an amide-linked amine
prepared by the condensation of a carboxylic acid with a di- or polyamine; or a
quaternary ammonium salt.

10 The compositions of the invention can take any form known in the art for the formula-
tion of agrochemicals, for example, a solution, a dispersion, an aqueous emulsion, a
dusting powder, a seed dressing, a dispersible powder, an emulsifiable concentrate or
granules. Moreover, it can be in a suitable form for direct application or as a
concentrate or primary composition which requires dilution with a suitable quantity of
15 water or other diluent before application.

An emulsifiable concentrate comprises the active ingredient dissolved in a water-
immiscible solvent which is formed into an emulsion with water in the presence of an
emulsifying agent.

20

A dusting powder comprises the active ingredient intimately mixed and ground with
a solid pulverulent diluent, for example, kaolin.

A granular solid comprises the active ingredient associated with similar diluents to
25 those which may be employed in dusting powders, but the mixture is granulated by
known methods. Alternatively it comprises the active ingredient absorbed or adsorbed
on a pre-granular diluent for example, Fuller's earth, attapulgite or limestone grit.

Wettable powders, granules or grains usually comprise the active ingredient in
30 admixture with a suitable surfactant and an inert powder diluent such as china clay.

Another suitable concentrate is a flowable suspension concentrate which is formed by grinding the active ingredient with water or other liquid, a wetting agent and suspending agent.

- 5 It is contemplated that the active compound of the invention may be applied in concentrations ranging from about 0.001 $\mu\text{g/ml}$ to 750 mg/ml, preferably from 1 $\mu\text{g/ml}$ to 10 mg/ml, for use in controlling fungi in plants.

For use in combating fungi in animals including mammals the active compounds of the
10 invention may be formulated by mixing a compound of the invention with suitable inert and compatible carriers known in the art for use in topical formulations, or for use as a systemic agent, as applicable.

The concentration of the active compounds of the invention described herein in the
15 compositions of the invention may vary within a wide range depending on the type of formulation and the field of application.

It is contemplated that the active compound of the invention may be applied in concentrations ranging from about 0.001 $\mu\text{g/ml}$ to 10 mg/ml, preferably from 0.1 $\mu\text{g/ml}$
20 to 1 mg/ml, for use in controlling fungi in animals.

In its fourth aspect the invention relates to methods of combating fungi in plants or animals including mammals, wherein an effective amount of a fungicidally active compound of the invention is applied to a region to be treated.

25

In connection with this aspect the compositions of the invention may for agronomical or horticultural uses be applied to a region to be treated either directly to the soil as a pre-emergence treatment to the seed surface as a seed dressing or to the foliage or fruits of the plants as a post-emergence treatment. Depending on the crop and cir-
30 cumstances the treatment may be postponed until seeds or fruits appear on the plants, wherein fungi are to be controlled.

The active preparation or the compositions of the invention can be applied directly to the plant by, for example, spraying or dusting either at the time when the fungus has begun to appear on the plant or before the appearance of fungus as a protective measure. In both such cases the preferred mode of application is by foliar spraying. It is generally important to obtain good control of fungi in the early stages of plant growth as this is the time when the plant can be most severely damaged. The spray or dust can conveniently contain a pre-or post-emergence herbicide, a mixture of other pesticides, plant growth regulators or fertilizers, if this is thought necessary.

10 Sometimes, it is practicable to treat the roots of a plant before or during planting, for example by dipping the roots in a suitable liquid or solid composition. When the active preparation of the invention is applied directly to the plant a suitable rate of application is from 0.001 to 50 kg per hectare, preferably from 0.05 to 5 kg per hectare.

15

In the method of the invention the active preparation of the invention alone or in combination with a conventional biocide can also be applied to seeds or habitat. Thus the preparation can be applied directly to the soil before, at or after drilling so that the presence of active ingredient in the soil can control the growth of fungi which may attack seeds.

20

The compositions may be applied in amounts corresponding to from about 1 g to about 100 kg fungicidally active compound per hectare.

25 When the soil is treated directly the active preparation (alone or in admixture with the conventional biocide) can be applied in any manner which allows it to be intimately mixed with the soil such as by spraying, by broadcasting a solid form of granules, or by applying the active ingredient at the same time as drilling by inserting it in the same drill as the seeds. A suitable application rate is within the range of from 0.01 to 50 kg per hectare, more preferably from 0.05 to 5 kg per hectare.

30

The concentration of the fungicidally active compounds of the invention in the compositions of the present invention when used alone or in combination with a conventional fungicide, as applied to plants is preferably within the range from about 0.001 to about 30 per cent by weight, especially 0.01 to 3.0 per cent by weight. In a
5 primary composition the amount of active compound can vary widely and can be, for example, in the range from about 5 to about 95 per cent by weight of the composition.

The concentration of the other fungicidally active ingredient in the mixed composition of the present invention, as applied to plants is preferably within the range of 0.001 to
10 50 per cent by weight, especially 0.01 to 10 per cent by weight. In a primary composition the amount of other active ingredient can vary widely and can be, for example, from 5 to 80 per cent by weight of the composition.

Although the present invention has been described in detail in connection with
15 controlling fungi in animals and plants, it is also anticipated that the fungicidally active compounds of the invention may be used for the preservation of wood by adding said compounds to wood preservation and/or impregnation compositions. Also, the active compounds of the invention may be useful as a fungicide and preservative in paints - both to prevent growth in the paint during storage, and growth on the painted object
20 such as the plastered surface of a house.

Further the fungicidally active compounds of the invention may due to their low toxicity be used for the preservation of cosmetics, foods and feeds, or other such items where the compounds may be added subsequent to any cooking process.
25

Also, the fungicidally active compounds of the invention may be used as fungicidal additive to growth media for various microorganisms such as *E. coli*, *Pseudomonas aeruginosa*, *Serpula lacrymans* and *Cladosporium sp.*

Description of the strain

Colonies: grey, cottony, sometimes zonate.

Conidiophores: Single to aggregated, simple, straight to flexuous, geniculate above.

5

Conidia: acropleurogenous, 2-4 septate when mature, smooth, but becoming verrucose on the large central cell, mostly curved, concolourous or with central cell more pigmented than the other cells, mostly 20-39 μ m long and 11-14 μ m thick in the broadest part.

10

CMI CC 337159 is 4 septate like *C. verruciformis*, but differs from it in the size of the conidia. The conidia of *C. verruciformis* are 16-26 μ m x 8-12 μ m in size. CMI CC 337159 is a new species in the genus *Curvularia*. It belongs to the class Deuteromycetes, sub-class Hyphomycetidae and family Dematiaceae.

15

Cultivation of the strain.

The fungus may be grown on agar slants containing the following ingredients in grams/litre:

20	yeast extract	4.0
	potassium dihydrogen phosphate	1.0
	magnesium sulphate heptahydrate	0.1
	glucose	15
	Bacto (Difco Laboratories, Detroit, USA) agar	20

25

This substrate is autoclaved at 121°C for 20 or 40 minutes and will, hereinafter, be referred to as YPG agar. Slants contain 12 ml YPG agar and after inoculation they are incubated at 20 - 25°C for 7 days or longer.

30 Fungicide production

A substrate for shake flasks was prepared using demineralized water with the following ingredients in grams per litre:

	yeast extract	4.0
	potassium dihydrogen phosphate	1.0
	magnesium sulphate heptahydrate	0.1
	glucose	15
5	pluronic® L61 (BASF, Federal Republic of Germany)	0.1

Sterilization took place at 121°C for 20 minutes. A 500 ml Erlenmeyer flask with 100 ml of substrate was inoculated with about 10⁶ spores from a YPG agar slant previously
10 inoculated with CMI CC 337159. The flasks were shaken at 230 rpm at 25°C for 3-7 days whereafter the fermentation broth was centrifuged. The supernatant containing the fungicide was thereby separated from the mycelium. Both the mycelium and the supernatant were analyzed for fungicidal activity.

15 The fungicide can also be produced in surface cultures in accordance with well known procedures.

The fermentation can also be carried out in media containing other sources of carbon and nitrogen assimilable by the micro-organism and generally low levels of inorganic
20 salts. In addition, the media may be supplemented with trace metals, although if complex sources of carbon and nitrogen are employed, they are usually present in the complex sources.

Extraction of the compound

25 Culture broth was drum filtered with High Flow Supercel® as precoat. To the filtrate was added 20 g/l XAD-8, and the mixture was stirred for 16 hours at 5°C.

The resin XAD-8, was then filtered off, and rinsed with 10 bed volumes 25% v/v ethanol with stirring for 30 minutes. The activity was first eluted with 2 x 3 volumes of
30 60% ethanol in 10 mM phosphate pH 7.0, and stirring for 60 minutes. The rest of the activity was eluted with 2 x 3 vol 80% v/v ethanol in 10 mM phosphate pH 7.0 and

stirring for 60 minutes. The eluates were combined and concentrated to 1/5 vol by vacuum evaporation at temperatures < 40°C.

3.6 litres of concentrated eluates were further concentrated to 750 ml. The concentrate
5 was then centrifuged and the precipitate was discarded. The supernatant was extracted twice with 765 ml ethyl acetate. The combined ethyl acetate phases were frozen to remove water.

The water free extract was concentrated by vacuum evaporation to 20 ml and then
10 added to 120 ml acetonitrile. Further concentration was done by vacuum evaporation to 25 ml, which was added to 70 ml deionized water and 70 ml ethanol, and vacuum evaporated until slightly cloudy. The solution was then placed in a refrigerator for crystallization. After 4 days the crystals were washed with deionized water and freeze
15 dried.

Thereby 1 g of crystals was obtained.

For simplicity the compound of formula IV hereinafter will be designated BK202.

20 Temperature and pH stability

Procedure: The compound BK202 was solubilized in buffer at the pHs indicated in Fig. 1, and then placed at 25 - 55°C for 16 hours. The buffers used were phosphate-citrate (T.C.McIlvaine, J. Biol. Chem. 49,183(1921), in the pH range 2.5 - 7 and from pH 7 -9.5 is used TRIS 0.05 M. After 16 hours, the samples were filtered on a membrane filter
25 0.45µm, and then analyzed by the HPLC method.

Figure 1 shows the relationship between residual activity and pH for a number of temperatures. From the figure it is seen that the compound of formula IV of the invention exhibit stability optimum about pH 7, where the stability seems independent
30 of temperature, whereas stability at pH values above 8 decreases rapidly. At pH values below 7 the stability decreases slowly except for the temperature 25°C, where the decrease seems to be rapid. However, this may reside in experimental error.

Analysis - HPLC method

Column: Spherisorb Hexyl 5 μ m, 140 mm x 4.6 mm
Flow: 1.5 ml/min
Detection: 220 nm and 210 nm
5 Eluent: 55% Acetonitrile + 0.1% Trifluor acetic Acid
Sample: 10 μ l
Retention time: ca. 6.3 minutes

Physical and chemical properties

10 Crystallization of the material, obtained by the isolation procedure previously described, from aqueous ethanol gives white crystals with the physico-chemical properties described below (oven dried at 80°C for two hours and stored overnight in a vacuum desiccator over anhydrous silica).

15 1. Physical properties

Nature colourless crystals

MP 194-195°C

20 $[\alpha]_D^{21}$ (C=0.4, MeOH) 205°

Analysis

Found C: 59.44

H: 8.14

N: 10.89

25 Calculated for C₅₆H₈₉N₉O₁₄·H₂O C: 59.50

H: 8.11

N: 11.15

30 Crystallization of the material from methanol yields anhydrous white crystals with the physico-chemical properties described below (oven dried at 80°C for two hours and stored overnight in a vacuum desiccator over anhydrous silica).

22

1. Physical properties

Nature colourless crystals

MP 210-212°C

5 $[\alpha]_D^{21}$ (C=0.4, MeOH) -227°AnalysisFoundC: 60.11H: 8.0010 N: 11.28Calculated for $C_{56}H_{89}N_9O_{14}$ C: 60.48

H: 8.06

N: 11.33

15

Mass spectrum (FAB) MH^+ 1112.6

2. Chemical properties

Total acid hydrolysis (6N HCl, 18-24 h, 110°C) yielded the following α -amino and

20 hydroxy acids (determined by Gas Chromatography/Mass Spectral analysis of trifluoroacetyl-n-butylester derivatives, numbers in parenthesis indicate the number of occurrences of each amino acid).

25	Lactate (1)	$C_3H_4O_2$
	Glycine (1)	C_2H_3NO
	Valine (1)	C_5H_9NO
	N-Me-Valine (3)	$C_6H_{11}NO$
	N-Me-Isoleucine (1)	$C_7H_{13}NO$
30	pipecolic acid (1)	C_6H_9NO
	N-Me-Aspartic acid (1)	$C_5H_7NO_3$
	O-Me-Tyrosine (1)	$C_{10}H_{11}NO_2$
		<hr/>
		$C_{56}H_{89}N_9O_{14}$

The compound BK202 of the invention is negative to ninhydrin-test, contains no -XH function that can be acetylated (Acetic anhydride/pyridine, 24 hours, room temperature) and has one free carboxyl group, which can be esterified by treatment with diazomethane to the corresponding monomethylester BK202-Me (Cf-PDMS, MH⁺ 1126.5).

The compound BK202 of the invention contains a lactone linkage (IR 1736 cm⁻¹) which can be opened by mild alkaline hydrolysis (0.1N NaOH; 0.5 h, room temperature) to yield a ring opened derivative BK202-OH. By treatment with diazomethane BK202-OH can be turned into the corresponding dimethylester BK202Me₂ (Cf-PDMS, MH⁺ 1158.4).

Spectral data

BK202

¹H-NMR: Due to the complexity of the spectra induced by the co-existence of more conformers only a partial assignment shown in Table I has yet been made.

TABLE IPartial assignment of the ^1H -NMR spectrum (Fig. 2)

Chemical shift values for major conformer relative to TMS (multiplicity (d=doublet, t=triplet, dd=double doublet, q=quartet, m=multiplet, br=broad), J-values in Hz)

Residue	NH	α -H	β -H	γ -H	others
5 O-MeTyr	7.50 (d, 10)	5.20 (m)	3.25 (2H, m)	----	7.00(2H, d, 8) 6.70(2H, d, 8)
10 Val	7.00 (d, 10)	4.55 (t, 10)	2.10 (m)	0.80, 0.89 (2 Me, d, 7)	----
15 Gly	7.08 (br)	4.02 (dd, 6/18)	----	----	----
NMe-Val	----	5.19 (d, 11)	2.37 (m)	0.88, 0.98 (2 Me, d, 7)	----
20 NMe-Val	----	4.31 (d, 10)	2.43 (m)	0.89, 1.06 (2 Me, d, 7)	----
NMe-Val	----	4.74 (d, 10)	2.13 (m)	0.68, ? (Me, d, 7)	----
25 Lac	----	5.47 (q, 7)	1.40 (Me, d, 7)	----	----

30 The ^1H -NMR-data are presented as raw spectra in Figures 2 to 4.

(Fig. 2, Fig. 3 and Fig. 4: 400 MHz spectra in CDCl_3 , DMSO-d_6 and CD_3OD , respectively).

^{13}C -NMR: 100.6 MHz in CDCl_3 (Fig. 5)

35 IR: KBr (Fig. 6)

Derivatives of BK202

BK202-Me

IR: KBr (Fig. 7)

Bioassay

10⁶ spores of *Botrytis cinerea* were added to 50 ml dilute salts comprising:

	ammonium hydrogen phosphate	66	mg
	potassium dihydrogen phosphate	68	-
5	dipotassium hydrogen phosphate	87	-
	calcium chloride-2-hydrate	7.4	-
	magnesium chloride-6-hydrate	10	-

Prior to the inoculation the salt solution was made up to 1 litre with distilled water and sterilized at 121°C for 20 minutes.

10

This was mixed with 50 ml YPG agar at a temperature which favoured the viability of *Botrytis* spores in the temperature range from 30°C to about 45°C where the agar is kept fluid without any harm to the spores. 12 ml of this mixture were poured into 9 cm petri dishes and allowed to solidify. 1-5 holes of 4 mm diameter were punched in the
15 agar and 15 µl culture broth was put in each hole.

The petri dishes were incubated at 20 - 25°C for 2 days. The presence of a fungicide will reveal itself as a clear non-growth zone around the holes - the larger the zone the stronger the fungicide. The supernatant of CMI CC 337159 under the conditions
20 described above, produced a rather diffuse zone with a diameter of 40 mm. Under a stereo microscope, it can be seen that the fungus is present but normal growth has been prevented. Under a light microscope the mycelium appears as large vesicles, suggesting a particular type of mode of action.

25 Mammalian pathogenicity

Culture broth containing the fungicide, viable spores and mycelium showed no effect on mice, intraperitoneally applied at the rate of 20 ml per kg body weight. The broth contained approximately 4.5x10⁷ viable counts /ml.

30 Toxicology

The toxicity of BK 202 was investigated in the following tests using the compound of formula IV in crystalline form:

- Acute oral and intravenous toxicity in mice, and
- Ames spot tests and in vitro testing of dermal irritation (Skintex®).

The animals were given the active ingredient in dosages up to 1600 mg/kg orally in a suspension, and up to 13 mg/kg in a solution applied intravenously to the tail.

Based on these tests the IC_{50} values for BK 202 were estimated as:

ATP > 10 μ g/ml;

Chemiluminescent > 10 μ g/ml

10

Consequently it can be concluded that BK 202 shows no indication of toxicity in the tests performed, and also BK 202 scored the lowest possible irritation in the Skintex® test.

15 Fungicidal activity

Experiments were carried out to determine the potency of the compound of formula IV towards various fungi. The active ingredient was dissolved in 60% ethanol and added to cooled potato dextrose agar to give final concentrations of 25, 5, 1, 0.2, 0.04 and 0.0016 μ g a.i. per ml agar, respectively. Control dishes contained no active

20 ingredient.

10 ml Agar was poured into 9 cm petri dishes and each concentration was inoculated with actively growing mycelium of the fungal isolates tested for. The dishes were incubated at the optimum temperature for growth of the isolates for 3 to 6 days after which time the growth was measured in mm and compared to the controls.

The test isolates covered a broad range of fungi within the *Oomycetes*, the *Ascomycetes*, the *Basidiomycetes*, the *Deuteromycetes*, and the *Zygomycetes*.

30 It was found that BK 202 was most active against fungi belonging to the *Ascomycetous* and the *Deuteromycetous* species. It was found to be particularly potent towards:

- Class Ascomycetes, genus *Venturia*, e.g. *V. inequalis*
 genus *Sclerotinia*, e.g. *S. sclerotiorum*
 genus *Monilinia*, e.g. *M. fructigena*,
 form-genus *Aspergillus*, e.g. *A. fumigatus*
 5 form-genus *Penicillium*, e.g. *P. digitatum*
- Class Deuteromycetes, genus *Botrytis*, e.g. *B. cinerea*
 genus *Ascochyta*, e.g. *A. pisi*
 genus *Pyrenophora*, e.g. *P. teres*
 genus *Cercospora*, e.g. *C. beticola* (weaker)
 10 genus *Phoma*, e.g. *P. sorghina* (weaker)
 genus *Alternaria*, e.g. *A. alternata* (weaker)
 genus *Fusarium*, e.g. *F. lycopersici* (weaker)

For the above fungi the inhibition was very strong in as low concentrations as 0.0016 $\mu\text{g/ml}$, except for *C. beticola*, *P. sorghina*, *A. alternata*, and *F. lycopersici*, where a
 15 weaker inhibition was found.

Only weak activity was found against *Zygomycetous* species, and practically no activity was found towards *Oomycetous* and *Basidiomycetous* species.

20 Biological activity on plants

At the concentrations used in the following examples no phytotoxic activity has been observed.

EXAMPLES

25

Example 1

Activity against *Botrytis cinerea* on tomato plants

Tomato plants (variety "First in Field", 3 weeks old) were treated with a liquid suspension containing 0.035 mg active ingredient per ml. The plants were kept 24
 30 hours in a green house to dry before they were inoculated with a spore suspension containing 10^5 *Botrytis cinerea* spores per ml in 25% grapefruit juice. The plants were then incubated for 6 days (16 hours light (1000 lux) and 8 hours dark at 15°C to 20°C)

in clear polyethylene bags to raise the relative humidity to 95 -100%.No attack from the fungus was observed. Control plants that were treated as above except for the application of the active ingredient in suspension were all overgrown with *Botrytis cinerea*.

5

Example 2

Activity against *Botrytis cinerea* on apples (Golden Delicious)

Artificially injured apples were sprayed with a suspension containing 9.8 μ g active ingredient per ml.On the following day the treated fruits were inoculated with a spore
10 suspension of the fungus containing 1×10^5 /ml, and incubated for a week at high air humidity and 18 - 20° C. At the evaluation the infected places of injury were counted and from that the fungicidal effect of the test substance evaluated. The active compound prevented the growth of fungus completely. The untreated fruits were 100% infected with *Botrytis cinerea*.

15

Example 3

Activity against *Botrytis cinerea* on strawberries (Senga-Sengana)

Field trial performed in Funen, Denmark, in accordance with the EPPO guidelines (Guideline for the Biological Evaluation of Fungicides. *Botrytis cinerea* on Strawber-
20 ries).

The plot size was 20 m² and three replicates were used. The active compound was used in a test formulation containing approximately 10% active ingredient (a.i.). Three concentrations of active compound were applied: 100, 300, and 900 g a.i./ha. The spraying
25 volume was 1200 l/ha.

The strawberries were sprayed at the following growth stages: T₁, onset of flowering; T₂, 10% flowering; T₃, 50% flowering; and T₄, 80% flowering.

30 The commercial fungicide ROVRAL® was used as standard reference.

The assessment was performed by counting and weighing healthy and infected strawberries, respectively.

The results are shown in Fig. 8, where the degree of infection is indicated for each of the tests. From Fig. 8 it is seen that BK 202 exhibited a superior fungicidal effect compared to ROVRAL®.

Example 4

Activity against *Botrytis cinerea* on grapes(Ugni Blanc)

10 Field trial performed in Bordeaux, France, in accordance with CEB Method No. 37.

A plot consisted of 15 plants in one row and six replicates were used. The active compound was used in a test formulation containing approximately 10% active ingredient (a.i.). Three concentrations of active compound were applied: 100, 300, and 15 900 g a.i./ha. The water volume was 300 l/ha.

The grapes were sprayed at the following growth stages: T₁, end of formation of bunches of grapes; T₂, beginning of ripening of grapes; and T₃, 3 to 4 weeks before harvest.

20

The commercial fungicides RONILAN® and BASULTRA® were used as standard references.

The assessment was performed by estimating the intensity and frequency of the *Botrytis cinerea* attack after the appearance of the disease.

The results are shown in Fig. 9, where the intensity of infection is indicated (defined as % attacked grapes in 100 bunches) for each of the tests. From Fig. 9 it is seen that BK 202 exhibited a superior fungicidal effect compared to both RONILAN® and 30 BASULTRA®.

Example 5

Activity against *Botrytis cinerea* on tomatoes (Matador)

Green house trial performed in Lyngby, Denmark.

- 5 A plot consisted of 7 plants (approximately 12 weeks old, 1 m high) and three replicates were used. The plants were kept in a plastic "tent" to maintain a high humidity. Before spraying the plants 20 leaves per plant were mechanically injured to improve the attack of *Botrytis cinerea*. The active compound was used in a test formulation containing approximately 10% active ingredient (a.i.). Three concentrations
10 of active compound were applied: 0.01%, 0.03%, and 0.09% a.i. The water volume was 770 ml/plot.

The tomatoes were sprayed just after wounding the leaves. 24 hours after fungicide treatment an artificial inoculation was done by spraying spores of *B. cinerea* suspended
15 in 30% orange juice on the plants.

The commercial fungicide RONILAN® was used as standard reference.

The assessment was performed by counting the number of attacks on leaves, stalks,
20 fruits, and flower buds.

The results are shown in Fig. 10, where the degree of infection is indicated for each of the tests. From Fig. 10 it is seen that BK 202 at all the tested concentrations exhibited a superior fungicidal effect compared to RONILAN®.

25

Example 6

Activity against fungicide resistant *Botrytis cinerea* isolates One isolate resistant to BENLATE® (isolate A), and one isolate resistant to BENLATE®, ROVRAL® and SUMISCLEX® (isolate B) were isolated from plants which had been sprayed with the
30 above mentioned pesticides. The effect of BK 202 on these isolates was determined in an *in vitro* assay and compared with the three commercial pesticides. The fungicides were added to agar and dispensed in petri dishes at different concentrations and were

inoculated with a sensitive (normal(isolate C)) and the two resistant strains. After 3 days at a temperature of 25 C growth was measured in mm.

The results are shown in Table II below.

5

TABLE II

Pesticide	concentration	Isolate A	Isolate B	Isolate C
BK 202	10	0	0	0
	2	0	0	0
	0.125	0	0	0
ROVRAL®	10	0	13	0
	2	0	46	0
BENLATE®	10	50	50	0
	2	65	62	0
10 SUMISCLEX®	10	0	35	0
	2	0	46	0
Control	-	76	80	74

Example 7

15 Activity against *Monilinia fructigena* on apples (Golden Delicious)

Apples were surface sterilized, each punctured 5 times with a nail 2.1 mm in diameter, dipped in suspensions containing 0, 0.5, 5, 50, and 500 mg a.i. per l. The active ingredient was (i) BK 202, (ii) benomyl(BENLATE®), (iii) iprodione(ROVRAL®). Four apples were punctured and treated with each concentration of the three
20 pesticides giving a total of 20 wounds per concentration. The fruits were placed in plastic containers in rows with the wounds facing upwards. After 24 hours, the wounded areas were sprayed with a suspension of *Monilinia fructigena* containing 1×10^5 spores per ml. The containers were then covered with polyethylene bags and kept at room temperature (approximately 22°C).

25

After 5 days the effects were assessed by counting the number of infected wounds (maximum 20 infected wounds per treatment).

The results are indicated in Table III.

TABLE III

	Concentration	BK 202	BENLATE®	ROVRAL®
5	0 mg ai/l	20	20	20
	0.5 mg ai/l	18	18	20
	5.0 mg ai/l	14	19	19
	50 mg ai/l	7	12	15
	500 mg ai/l	1	3	4

10


From Table III it can be seen that the activity of BK 202 towards *M. fructigena* is superior in comparison to the two commercial fungicides tested.

Examples of further crops considered protectable against fungal attacks are:

- 15 pears, plums, peaches, cherries, raspberries, beans, peas, soya, oil cultures like rape, mustard, olives, sunflowers etc., cereals, cucumbers, melons, citrus fruits like oranges, lemons, mandarin oranges etc., spinach, lettuce, potato, pepper, avocado, aubergine, banana, composites like gerbera and other ornamental plants etc.

International Application No: PCT/


/

MICROORGANISMS	
Optional Sheet in connection with the microorganism referred to on page <u>6</u> , line <u>9</u> of the description:	
A. IDENTIFICATION OF DEPOSIT:	
Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution:	
C.A.B. INTERNATIONAL MYCOLOGICAL INSTITUTE	
Address of depositary institution (including postal code and country):	
Ferry Lane, Kew, Surrey TW9 3AF, UK	
Date of deposit:	Accession Number:
6 February 1990	CMI CC No. 337159
B. ADDITIONAL INDICATIONS: (leave blank if not applicable). This information is continued on a separate attached sheet <input type="checkbox"/>	
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).	
C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE: (If the indications are not for all designated States)	
D. SEPARATE FURNISHING OF INDICATIONS: (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later: (Specify the general nature of the indications e.g. "Accession Number of Deposit")	
E. <input type="checkbox"/> This sheet was received with the international application when filed (to be checked by the receiving Office)	
 (Authorized Officer)	
<input type="checkbox"/> The date of receipt (from the applicant) by the International Bureau is:	
_____ (Authorized Officer)	


PATENT CLAIMS

1. Novel compounds of the general composition I,
Lactic acid (1), Glycine (1), Valine (4), Isoleucine (1),
5 pipecolic acid (1), Aspartic acid (1), Tyrosine (1) (I)
wherein each amino acid residue independently may occur in L- or D-form, and
wherein the number in parenthesis indicates the number of occurrences of each
moiety, and derivatives thereof.
- 10 2. Compounds according to claim 1 further comprising a lactone ring; and
derivatives thereof.
3. Compounds of claim 1 or 2 having the composition $C_{56}H_{89}N_9O_{14}$ and
derivatives thereof.
- 15 4. Compounds of claim 1, 2, or 3, wherein said derivatives comprises such
compounds having been alkylated, acylated, hydroxylated, glycosylated, halogenated,
reduced, oxidized, hydrolysed, esterified or amidated.
- 20 5. Compounds of claim 1, 2, or 3, of the general composition II
Lactate (1), Glycine (1), Valine (1), N-Me-Valine (3),
N-Me-Isoleucine (1), pipecolic acid (1), N-Me-Aspartic acid (1), (II)
O-Me-Tyrosine (1).
wherein each amino acid residue independently may occur in L- or D-form, and
25 wherein the number in parenthesis indicates the number of occurrences of each
moiety, and derivatives thereof.

6. The compounds of formulae III or IV



cyclo-[Pec-MeAsp-MeVal-Val-MeVal-Melle-Gly-MeVal-TyrOMe-D-Lact] (III)



5 cyclo-[Pec-MeVal-Val-MeAsp-MeVal-Melle-Gly-MeVal-TyrOMe-D-Lact] (IV),

wherein each amino acid residue and the lactate residue independently may occur in L- or D-form, and derivatives thereof, preferably the compounds of formulae III or IV, wherein all the amino acid residues are in the L-form and the lactate residue is in the D-form.

5

7. A process for the production of compounds according to any of the claims 1 to 6 by

- a) cultivation on suitable nutrient media under suitable conditions of a species belonging to the genus *Curvularia*,
- 10 b) subsequent recovery of the active component from the biomass and the fermentation medium, and
- c) optionally modifying the active compound to obtain a desired compound.

15 8. The process of claim 7, wherein the active compound has the formula III or IV, and is obtained directly in step (b).

9. The process of claim 7, wherein the modification of step (c) comprises glycosylation of one or more groups in the compound obtained in step (b) into one or more
20 sugar containing moieties.

10. The process of claim 7, wherein the modification of step (c) comprises acylation of one or more groups in the compound obtained in step (b) with an organic acid of formula $R^1\text{-COOH}$, wherein R^1 is hydrogen or an organic group with 1 to 5
25 carbon atoms, providing compounds, wherein one or more groups are ester groups with 1 to six carbon atoms.

11. The process of claim 7, wherein the modification of step (c) comprises alkylation of one or more groups in the compound obtained in step (b) providing
30 compounds, wherein one or more groups are alkyl groups with 1 to six carbon atoms.

12. The process of claim 7, wherein the modification of step (c) comprises halogenation of one or more groups in the compound obtained in step (b) providing compounds, wherein one or more groups are halogens.
- 5 13. The process of claim 7, wherein the modification of step (c) comprises reduction of one or more groups in the compound obtained in step (b).
14. The process of claim 7, wherein the modification of step (c) comprises oxidation of one or more groups in the compound obtained in step (b).
- 10 15. The process of claim 7, wherein the modification of step (c) comprises hydrolysis of one or more groups in the compound obtained in step (b).
16. The process of any of the claims 7 to 11, wherein the microorganism is
15 *Curvularia sp.* (CMI CC No. 337159).
17. A fungicidal composition comprising as an active ingredient a compound of any of claims 1 to 6.
- 20 18. The composition of claim 17, wherein said compound is present in an amount of from 0.001 $\mu\text{g/ml}$ to 100 $\mu\text{g/ml}$.
19. A fungicidal composition comprising as an active ingredient a fungus of a species belonging to the genus *Curvularia*.
- 25 20. The composition of claim 19, wherein the fungus is *Curvularia sp.* (CMI CC No. 337159).
21. A fungicidal composition comprising as an active ingredient a compound of
30 any of claims 1 to 6 in combination with other biocidal agents.

22. The composition of claim 21, wherein said other biocidal agent is chosen from the group comprising pesticides, such as fungicides, herbicides, insecticides, nematocides, acaricides or plant nutrients, plant growth regulators and fertilizers.

5 23. The composition of claim 21, wherein said other biocidal agent is another fungicide chosen from the group comprising ergosterol biosynthesis inhibitors ("EBIs", azoles or non-azoles), anilides, benzimidazoles, carbamates, dicarboximides, dithiocarbamates, bisdithiocarbamates, imidazoles, triazoles, phthalonitriles, polyhalogenalkylthio compounds, and phosphorous derivatives.

10

24. The composition of any of the claims 21 to 23, wherein said other active agent is present in an amount of 0.001 to 50% by weight, preferably 0.01 to 10% by weight.

25. A method of combating fungi at a locus infested or liable to be infested
15 therewith, which comprises applying to said locus a composition according to any of the claims 17 to 24.

26. The method of claim 25, for combating fungi in plants, on timber, cosmetics, feeds and foods.

20

27. The method of claim 25 or 26, to control attacks from fungal species belonging to the classes Ascomycetes, or Deuteromycetes.

28. The method of claim 25, 26, or 27, to control attacks from fungal species
25 belonging to the genera Venturia, Sclerotinia, Monilinia, Aspergillus, Penicillium, Botrytis, Ascochyta, Pyrenophora, Cercospora, Phoma, Alternaria or Fusarium.

29. The method of claim 28. to control attacks from fungal species belonging to the genus *Botrytis*, especially *Botrytis cinerea*.
30. Use of a compound of any of the claims 1 to 6 for treating plants.
- 5 31. Use of a compound of any of the claims 1 to 6 for the preservation of wood or timber.
32. Use of a compound of any of the claims 1 to 6 for the preservation of paints.
- 10 33. Use of a compound of any of the claims 1 to 6 for the preserevation of cosmetics.
34. Use of a compound of any of the claims 1 to 6 for the preservation of foods
- 15 and feeds.
35. Use of a compound of any of the claims 1 to 6 as an additive to growth media.
- 20 36. An isolated pure culture of the microorganism *Curvularia sp.*(CMI CC No. 337159).

1/10

Temperature/pH - Stability Residual Activity




Fig. 1




Fig. 2




Fig. 3

4/10




Fig. 4





Fig. 5

6/10



REPLACEMENT SHEET

7/10




Fig. 7

8/10




Fig. 8

9/10




Fig. 9

10/10







Fig. 10

INTERNATIONAL SEARCH REPORT

International Application No PCT/DK 91/00273

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 07 K 11/02, C 12 P 21/04, A 01 N 63/04, C 12 N 1/14 // (C 12 P 21/04, C 12 R 1:645) (C 12 N 1/14, C 12 R 1:645)											
II. FIELDS SEARCHED <div style="text-align: center;">Minimum Documentation Searched⁷</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 20%; border: none;">Classification System</td> <td style="border: none;">Classification Symbols</td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">IPC5</td> <td style="border: 1px solid black; padding: 5px;">A 01 N; C 07 K; C 12 P</td> </tr> </table> <div style="text-align: center; padding-top: 5px;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in Fields Searched⁸</div>			Classification System	Classification Symbols	IPC5	A 01 N; C 07 K; C 12 P					
Classification System	Classification Symbols										
IPC5	A 01 N; C 07 K; C 12 P										
SE,DK,FI,NO classes as above											
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category¹⁰</th> <th style="width: 70%;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 20%;">Relevant to Claim No.¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td style="vertical-align: top;">EP, A2, 0360760 (SANDOZ-ERFINDUNGEN) 28 March 1990, see the whole document --</td> <td style="text-align: center; vertical-align: top;">1-16</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td style="vertical-align: top;">EP, A1, 0207653 (MYCOGEN CORPORATION) 7 January 1987, see the whole document -- -----</td> <td style="text-align: center; vertical-align: top;">17-36</td> </tr> </tbody> </table>			Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	A	EP, A2, 0360760 (SANDOZ-ERFINDUNGEN) 28 March 1990, see the whole document --	1-16	A	EP, A1, 0207653 (MYCOGEN CORPORATION) 7 January 1987, see the whole document -- -----	17-36
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³									
A	EP, A2, 0360760 (SANDOZ-ERFINDUNGEN) 28 March 1990, see the whole document --	1-16									
A	EP, A1, 0207653 (MYCOGEN CORPORATION) 7 January 1987, see the whole document -- -----	17-36									
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents:¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document is member of the same patent family</p> </div> </div>											
IV. CERTIFICATION <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border: none;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">20th December 1991</td> <td style="border: 1px solid black; padding: 5px; text-align: center;">1991-12-23</td> </tr> <tr> <td style="border: none;">International Searching Authority</td> <td style="border: none;">Signature of Authorized Officer</td> </tr> <tr> <td style="border: 1px solid black; padding: 5px; text-align: center;">SWEDISH PATENT OFFICE</td> <td style="border: 1px solid black; padding: 5px;">  Elisabeth Carlberg </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	20th December 1991	1991-12-23	International Searching Authority	Signature of Authorized Officer	SWEDISH PATENT OFFICE	 Elisabeth Carlberg	
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report										
20th December 1991	1991-12-23										
International Searching Authority	Signature of Authorized Officer										
SWEDISH PATENT OFFICE	 Elisabeth Carlberg										

Form PCT/ISA/210 (second sheet) (January 1985)

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.PCT/DK 91/00273

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the Swedish Patent Office EDP file on 31/10/91
The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A2- 0360760	90-03-28	AU-D- 4165289	90-04-05
		DE-A- 3832362	90-03-29
		JP-A- 2134399	90-05-23
EP-A1- 0207653	87-01-07	JP-A- 62000407	87-01-06
		US-A- 4775405	88-10-04
		US-A- 4776873	88-10-11

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.